# A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

> **NCT01248455** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Multiple Myeloma
- Myeloma
- Smoldering Multiple Myeloma

## Interventions

- **DRUG:** (Anti-KIR)

## Key facts

- **NCT ID:** NCT01248455
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-01
- **Primary completion:** 2014-05-01
- **Final completion:** 2015-04
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of patients meeting the defined primary obj. (50% decline in M-protein).
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01248455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01248455, "A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01248455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*